The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Looks like the SP has formed a good solid base at 10-11p going into the new year. With all the spike in admissions definitely a good likelihood that we might reach the 100 patient unblinding target sooner than anticipated possibly in January, so expect it to be a very volatile month with an upward drift.
Hi all, I am a new investor to this company. I have done some basic research on this company reading through some of the recent RNS. To me the company seems to be massively undervalued, given that it is a company actually producing gold and looking at the previous profits made by the firm.
I understand there have been some recent disappointments and hurdles especially missing on production targets, but these seem to be of a temporary nature and seems a bit of an over reaction on the SP in my view. I understand some of the II's may also be offloading further leading to this downside pressure.
Based on what I have read, while there are risks with this investment, I think the upside potential also looks very good if someone is willing to be patient.
However I don't think I have a full understanding of the company, and hence have only made a small investment based on the limited research I have done, especially as the price was looking very attractive and I can hold for the medium term.
I may be perhaps missing the whole picture, but is there some other historic issues other than the ones stated in the most recent RNS releases causing the SP to go down? Thanks.
The RNS mentions that Both primary endpoints have at least 90% power to detect a statistically significant effect of SNG001 compared to placebo
Is this in relation to the required p value for the trial? Slightly confused about the p value of 0.025 required which I believe was being discussed last week and if it was related to this statement in the RNS.
Thanks Max, seems plausible that behind the scenes it may not be a small deal given that a 1bn $ Nasdaq listed company has released an announcement for it, and is already confident of its success. Don't see any reason for TRHC to announce it if they were talking about a couple of £100k annual payment at best, as it's not news worthy enough for them to announce. A buyout definitely has a good likelihood as you say. Time will obviously tell but the next few weeks will be very interesting both on the news and the SP movement.
Hi all, First time poster in this BB. I have a very small investment here bought many months back as PYC seemed like an interesting proposition and was pleasantly surprised this evening looking at the SP.
Does anyone have any rough estimate of what sort of potential commercial value this partnership could have. Looking at TRHC's financials their revenue has achieved compound growth from 100m $ in 2016 to nearly 300m $ in 2019, and their website suggests Dosemerx is one of their main products, although not sure of the revenue contribution.
Does anyone have any further knowledge about them?
Appreciate the RNS mentioned about an initial trial first, but given the positive history of PYC with other majors there is great potential for PYC to succeed. With the explosive revenue growth of TRHC, even a small % revenue sharing agreement may end up being more than PYCs current mcap, suggesting there is a lot of upside to the SP.
Gla, hope this will be a potential multibagger.
That is brilliant news, cheers Josh for sharing. I am sure using the word "imminently" in their reply has bought a welcome relief to a lot of folks including myself. Seems like the FDA approval must be there by now to go ahead.
Slowly chipping away upwards, but so far looks like 10p is a bit of a resistance. Hopefully we will clear that soon and someday laugh that the SP even existed at these ridiculous level.
The unblinding after 100 patients is going to a very interesting milestone. The trial has done well to recruit 9 in about 2 weeks, and with the onset of winter, the uptake should hopefully pick up further. Reckon Feb would be a very exciting month.
Anyone has any thoughts on why the UK arm of the phase 3 trial has not started yet?
Just seen that the NIHR site shows the trial was already approved on 14 October, but is still shown as in setup.
https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=290965
Given its been 2 months since approval and has been accorded urgent status, it does seem to be taking a very long time for the UK arm to start.
Could it be that the trial whether UK or international is being universally designed to satisfy all regulators worldwide which means any arm will not start until all regulators are happy and approved the overall design?
Given the international arm will be held in 20 countries, it does seem like an awful lot of regulatory hurdles to clear if that is the case.
Still remain hopeful that the UK arm will at least start soon, but the 14th Oct approval date does come as a surprise.
My guess is that they bought at around £2ish and then anticipated that the speed of vaccine development would have resulted in a big hit in the absence of an emergency authorisation for SNG or phase 3 progress so sold off at a loss.
Did the MMs take out a stop loss at 3p? The seller must be out today.
I think I am in a similar position to you, being very overweight here at about the placing price average with no scope to average down, so definitely lesson learned to always hold some fire rather than go all in, as the current levels are really good for anyone wanting to now enter. What surprised me is the ongoing panic and speed of SP moving down, I was expecting to see these levels if we do end up with a phase 3 failure not earlier. Still don't fully understand what the panic is about, it's almost as if the market has already largely priced in that there won't be a phase 3 trial now or will already be a failure when completed which will be a surprise given the phase 2 results.
Is there any possibility for a new placing going on in the background?pure speculation on my part but would obviously benefit the big II's the lower the price while shafting the PIs